We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia for the treatment of relapsing- remittingMS or secondary progressive MS with continued relapses in adult patients, provided on the NHS in England and Wales.